{"id":"placebo-matching-atogepant","safety":{"commonSideEffects":[{"rate":null,"effect":"Constipation"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Upper respiratory tract infection"}]},"_chembl":{"chemblId":"CHEMBL3991065","moleculeType":"Small molecule","molecularWeight":"603.52"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Atogepant works by antagonizing the calcitonin gene-related peptide receptor, a key mediator in migraine pathophysiology. By blocking CGRP receptor signaling in the central and peripheral nervous system, it reduces the frequency and severity of migraine attacks. This oral small-molecule approach provides preventive migraine therapy.","oneSentence":"Atogepant is a calcitonin gene-related peptide (CGRP) receptor antagonist that blocks CGRP signaling to prevent migraine.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:51:30.336Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Migraine prevention in adults"}]},"trialDetails":[{"nctId":"NCT05711394","phase":"PHASE3","title":"A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine","status":"RECRUITING","sponsor":"AbbVie","startDate":"2023-05-01","conditions":"Episodic Migraine","enrollment":450},{"nctId":"NCT04740827","phase":"PHASE3","title":"Atogepant for Prophylaxis of Migraine in Participants Who Failed Previous Oral Prophylactic Treatments.","status":"COMPLETED","sponsor":"Allergan","startDate":"2021-03-05","conditions":"Episodic Migraine","enrollment":315},{"nctId":"NCT03855137","phase":"PHASE3","title":"Efficacy, Safety, and Tolerability of Atogepant for the Prevention of Chronic Migraine","status":"COMPLETED","sponsor":"Allergan","startDate":"2019-03-11","conditions":"Chronic Migraine","enrollment":778},{"nctId":"NCT03777059","phase":"PHASE3","title":"12-Week Placebo-controlled Study of Atogepant for the Preventive Treatment of Migraine in Participants With Episodic Migraine","status":"COMPLETED","sponsor":"Allergan","startDate":"2018-12-14","conditions":"Episodic Migraine","enrollment":910},{"nctId":"NCT02848326","phase":"PHASE2, PHASE3","title":"Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant (AGN-241689) in Episodic Migraine Prevention","status":"COMPLETED","sponsor":"Allergan","startDate":"2016-09-06","conditions":"Migraine, With or Without Aura","enrollment":834}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo-Matching Atogepant","genericName":"Placebo-Matching Atogepant","companyName":"AbbVie","companyId":"abbvie","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Atogepant is a calcitonin gene-related peptide (CGRP) receptor antagonist that blocks CGRP signaling to prevent migraine. Used for Migraine prevention in adults.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}